TMPRSS2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse kidney tissue lysate, Primary antibody: P01672(TMPRSS2 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P01672(TMPRSS2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of TMPRSS2 Antibodies**

TMPRSS2 (Transmembrane Serine Protease 2) is a cell surface-associated protease belonging to the type II transmembrane serine protease family. It plays a critical role in proteolytic activation of viral envelope proteins, including SARS-CoV-2 spike protein, facilitating viral entry into host cells. TMPRSS2 is also implicated in prostate cancer, where its fusion with the ERG oncogene (TMPRSS2-ERG) is a common driver event.

Antibodies targeting TMPRSS2 are essential tools for studying its expression, localization, and function. They are widely used in research to investigate its role in viral pathogenesis (e.g., COVID-19) and cancer progression. In COVID-19 studies, TMPRSS2 antibodies help evaluate the protease’s interaction with viral proteins and assess therapeutic strategies, such as protease inhibitors. In oncology, these antibodies aid in detecting TMPRSS2-ERG fusion proteins, which are biomarkers for prostate cancer diagnosis and prognosis.

Commercial TMPRSS2 antibodies are typically raised against specific epitopes in its extracellular or cytoplasmic domains. Validation includes testing in applications like Western blotting, immunohistochemistry, and flow cytometry. Cross-reactivity with homologous proteases (e.g., TMPRSS4) must be ruled out to ensure specificity. Recent advancements in monoclonal antibody development have improved target selectivity, supporting both basic research and clinical investigations.

Overall, TMPRSS2 antibodies remain pivotal in unraveling its dual role in infectious diseases and cancer, offering insights for therapeutic targeting and biomarker discovery.